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abstract
Keywords:

Comparisons between Asian American and Pacific Islander (AAPI) and, when possible,

Collaborative research

similar populations from their ancestral land of origin may allow for unique insights into

Hmong

the development of substance use disorders. Drawn from research conducted within the

Opiate dependence

Hmong residing in the United States of America (USA) and from ongoing collaborative work

Psychiatric disorder

between the USA and Vietnam, this paper presents a few examples of the types of
addiction research that may be possible in Asian populations, both in the USA and in Asia,
with a focus on developing South East Asian countries and their AAPI counterparts in the
USA. Approaches to research may include epidemiological surveys, evaluation of treatment need and outcome, and genetic contributors to the risk for substance use disorders
(SUDs) as well as response to SUD treatment.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. All rights reserved.

1.

Introduction

The United States of America (USA) is a land of immigrants.
Approximately 15 million Americans identify as Asian
American and Pacific Islander (AAPI). Between 2000 and 2010,
the AAPI population in the USA grew by 43%, and it is expected
to grow by another 134% over the next 40 years (http://www.
whitehouse.gov/sites/default/files/docs/infographic_1.pdf).
Thus, understanding the risks for, protections from, and
treatment of substance use disorders in this population will be
of increasing importance. Although historically AAPI have had
lower levels of exposure to alcohol and other drugs than other
US populations, the pressures of immigration, cultural diversity, the impact of being stereotyped as the “model” population, and genetic bottlenecks create both opportunities and
needs for addiction research.
Comparisons between AAPI and, when possible, similar
populations from their ancestral land of origin may allow

for unique insights into the development of substance use
disorders. The focus of this paper is to present a few examples of the types of addiction research that may be
possible in Asian populations, both in the USA and in Asia,
with a focus on developing South-East Asian countries and
their AAPI counterparts in the USA. Approaches to research
may include epidemiological surveys, evaluation of treatment need and outcome, and genetic contributors to the
risk for substance use disorders (SUDs) as well as response
to SUD treatment.

2.

Approaches to addiction research

Identifying populations who use alcohol and other drugs is an
early step in a diversity of addiction-related research. Epidemiological surveys and diagnostic assessments can help
determine the extent of drug use and addiction in a
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population. Among the Hmong of South-East Asia, the estimated prevalence of opiate dependence in Laos, Thailand, and
the USA is 10%, 15%, and 3%, respectively [1e4]. However,
these data were collected across wide time ranges and in
populations with differing modes of opiate consumption (i.e.,
opium smoking in Laos and the USA versus heroin injection in
Thailand), so it is not clear how informative these numbers
are in comparing the Hmong across these regions. In addition,
the diagnostic instrument used in Thailand was specifically
validated for the Hmong, whereas the instruments used in
Laos and the USA, although valid in general populations, had
not been validated in the Hmong. Therefore, future attempts
to collect data across populations will benefit from cohort
studies using standardized and validated instruments.
In addition to determining the prevalence of SUDs in a
specific AAPI population in the USA, it may be of interest to
compare AAPI populations with a given diagnosis to non-AAPI
populations. This may help identify specific treatment needs
and risk and protective factors within the population. For
example, Westermeyer and Chitasombat [5] compared US
Hmong entering treatment for opiate dependence to a population of non-Hmong entering the same treatment facility and
found a significantly greater burden of psychopathology as
assessed by the Beck Depression Inventory, Hamilton
Depression and Anxiety Rating Scales, and Symptom
Checklist-90 scores. Bart et al (unpublished) compared psychiatric diagnoses between Hmong and non-Hmong attending
a single methadone maintenance clinic in Minnesota and
found that although there was no difference in ongoing SUD
diagnoses, the Hmong were less likely to have an Axis 1
diagnosis, and, of those who did have an Axis 1 diagnosis,
there was a lower prevalence of depressive and anxiety disorders. The next question that can be asked is whether these
differences influence the response to SUD treatment.
The treatment of opiate dependence in Hmong using solely
behavioral approaches has been poor, with relapse rates
exceeding 70% [6,7]. This has been observed in Hmong in Laos as
well as Hmong in the USA, and this poor response rate is similar
to rates observed in non-Hmong populations [8]. We found that
Hmong receiving methadone maintenance, however, have
significantly greater 1-year retention in treatment (a common
metric of treatment response) than do non-Hmong attending
the same US clinic [9]. Interestingly, this response was achieved
on lower doses of methadone than their non-Hmong counterparts. This is slightly paradoxical in that patients on higher
methadone doses tend to have better responses than those on
lower doses [10]. Thus, a simple observational study of differential treatment response has led to studies of biological differences in methadone pharmacology between Hmong and
non-Hmong. Because the Hmong remain relatively nonadmixed from a genetic standpoint [11], these studies may also
allow for the discovery of genetic influences on methadone
pharmacology and treatment response.
We hypothesized that the Hmong required lower methadone doses because the apparent oral clearance of methadone
was lower in Hmong than non-Hmong. This hypothesis was
not confirmed, but rather we found that the Hmong had a
higher relative bioavailability than non-Hmong, which also
fits with a lower dose requirement [12]. Although we did not

S107

find genetic influences on methadone pharmacokinetics that
were unique to Hmong, we confirmed reductions in apparent
oral clearance of total methadone in carriers of the ATPBinding Cassette-B1 (ABCB1) 2677GG genotype and of the inactive S-methadone enantiomer in carriers of the Cytochrome
P450 2B6 (CYP2B6) 516T allele.

3.

Conclusions

Future steps would be to expand these lines of inquiry to other
AAPI populations and other SUD diagnoses. Partnering with
researchers in the countries of origin can help refine the
questions to be asked, gain larger populations to allow for
more powerful studies, and compare the effect of social forces
between populations that have become separated through
time, culture, and geography. Although not all regions have a
developed research infrastructure, the US National Institute
on Drug Abuse provides an online forum for international
researchers to help promote collaboration (http://international.
drugabuse.gov/). In addition, the National Institutes of Health
has several research training materials that are freely
available online to assist those who may have limited resources or must train nonresearch oriented staff (http://www.
esourceresearch.org/tabid/36/Default.aspx). Through combined efforts we may not only improve the health of AAPI
populations but of other populations, both in the USA and
around the world.
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